XENE vs XERS Stock Comparison

XERS currently leads XENE in this stock comparison, with AIQ scores of 78 vs 49. The clearest difference is momentum.

Market data as of Nov 15, 2026 market close· AIQ score gap 29 points
XENE
Healthcare
vs
XERS
Healthcare
XENE
Xenon Pharmaceuticals Inc.
Price
$40.48
Day move
-1.26%
AIQ Score
49/100
Best edge
Balanced
Sector
Healthcare
XERS
Xeris Biopharma Holdings, Inc.
Leads
Price
$16.66
Day move
+0.06%
AIQ Score
78/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between XENE and XERS?

XERS leads the current stock comparison as Xeris Biopharma Holdings, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Xenon Pharmaceuticals Inc. vs Xeris Biopharma Holdings, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 9/10

XERS leads

XERS leads by 29 AIQ points, primarily on Momentum and Risk Resilience. Wall Street currently favors XENE on target upside.

Stable: 4 of 5 evidence groups support XERS, and its current signal state is conflicted.

Evidence agreement: 4 of 5Comparison trend: Stable
XENE

Xenon Pharmaceuticals Inc.

AIQ Score
49/100
AIQ Edge Score
8/10
XERS

Xeris Biopharma Holdings, Inc.

Leads
AIQ Score
78/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors XERS over XENE, 78 versus 49 as of Nov 15, 2026. XERS's advantage is driven primarily by stronger momentum and risk resilience. XERS also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors XENE. 4 of 5 covered evidence groups favor XERS today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. XERS lead: Stable — the AIQ differential has held near 29 points over 30 sessions.

Compare Xenon Pharmaceuticals Inc. and Xeris Biopharma Holdings, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

XENE
+32.2%
XERS
+580.0%

Price return comparison

Growth of $10,000, price only

XENE $13,216 · XERS $68,000

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare XENE and XERS against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

XENE advantage
0
XERS advantage
  • Momentum33 vs 98
    XERS +65
  • Risk Resilience49 vs 55
    XERS +6
  • Quality68 vs 71
    Even

4 of 5 evidence groups favor XERS. XERS’s edge is concentrated in momentum and risk resilience.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

XENE0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)
XERS+1 AIQ

Largest factor move: Value +1

No signal started or stopped since the prior session; its 9 active signals are unchanged.

XERS's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — XENE and XERS both carry a full feed there.

The central trade-off

XERS (Xeris Biopharma Holdings, Inc.): the stronger current systematic profile, led by momentum and risk resilience.

XENE (Xenon Pharmaceuticals Inc.): the counter-case, on analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

XERS

XERS on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

XERS

XERS on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

XERS

XERS on the Momentum factor, by 65 points.

Lower downside

XERS

XERS on Risk Resilience, by 6 points.

Analyst upside

XENE

XENE on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors XERS, analyst targets favor XENE. That disagreement is the most useful thing on this page.

MeasureXENEXERSNote
Implied upside to target+67.6%-10%XENE has more room
Target dispersion+64.8%+13.3%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering187Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 5 covered evidence groups favor XERS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreXERS49 vs 78
FundamentalsXERSTTM ROE -9.6% vs 23.1%
ValuationNot coveredNot covered
TechnicalsXERSPrice vs 50-day -1.6% vs 60.1%; vs 200-day -22.6% vs 112.8%
Risk ResilienceXERSRisk Resilience 49 vs 55
Analyst expectationsXENETarget upside 67.6% vs -10%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of XENE and XERS and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 29 points. (supports the conclusion holding)
  • 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XERS.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

XERS lead: Stable — the AIQ differential has held near 29 points over 30 sessions.

May 27XENE leads above the line · XERS leads belowNov 13
Today
XERS +29
49 vs 78
7 sessions ago
XERS +28
49 vs 77
30 sessions ago
XERS +30
46 vs 76
90 sessions ago
XENE +2
73 vs 71

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

XENE

0 bullish / 3 bearish / 2 neutral

Only XENE

  • Death Cross Active — bearish, trend, long horizon (27.10%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Downtrend Structure Active — bearish, trend, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)
XERSConflicted

6 bullish / 1 bearish / 2 neutral, conflicted

Only XERS

  • Golden Cross Active — bullish, trend, long horizon (32.87%)
  • 52-Week High Proximity — bullish, risk_regime, long horizon (0.7%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Keltner Channel Breakout — bullish, volatility, short horizon
  • RSI Overbought — bearish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

XERS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

XENENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).

XERSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.06%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1XENE closes the Momentum gap — currently 65 points behind, the largest single contributor to XERS's edge.
  2. 2XENE's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

XERS leads on balance
MetricXENEXERS
Revenue growth (YoY)0%16.4%
EPS growth (YoY)0%133.3%
Gross margin0%84.4%
Operating margin0%12.7%
Return on equity (TTM)-9.6%23.1%
Debt to equity0.014.63

Performance

XERS leads 6 of 6 windows
MetricXENEXERS
1 week (5 sessions)3.3%9.6%
1 month (20 sessions)20.9%61.6%
3 months (63 sessions)-35.1%95.5%
6 months (126 sessions)-25.6%167%
Year to date-9.7%112.2%
1 year (252 sessions)2%119.5%

Technicals

XERS has the stronger structure
MetricXENEXERS
RSI (14)54.985.4
ADX (14)2447
Price vs 50-day-1.6%60.1%
Price vs 200-day-22.6%112.8%
Volatility (1M, annualized)38%110.3%

Risk

XERS is the more resilient
MetricXENEXERS
Beta0.860.07
Sharpe ratio0.271.67
Sortino ratio0.482.99
Max drawdown-52.8%-34.9%
Current drawdown-43%0%
Annualized volatility68.1%57%
Value at risk (95%)-3.3%-4.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, XENE or XERS?

On the Algovestiq AIQ Score, XERS is the stronger of the two as of Nov 15, 2026, scoring 78 against XENE's 49. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is XENE or XERS the better buy right now?

XERS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 4 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor XERS over XENE?

The composite weights Quality, Value, Momentum and Risk Resilience. XERS leads Momentum by 65 points; XERS leads Risk Resilience by 6 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, XENE or XERS?

Analyst price targets imply +67.6% upside for XENE and -10% for XERS, so the Street currently favors XENE. That points the opposite way to the AIQ Score, which favors XERS. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, XENE or XERS?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, XENE or XERS?

XERS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, XENE or XERS?

XERS on the Momentum factor, by 65 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, XENE or XERS?

XERS is the more resilient of the two, so the other name carries the higher downside risk. XERS on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is XENE more profitable than XERS?

XERS leads on the comparable margin measures — gross margin 0% vs 84.4%; operating margin 0% vs 12.7%; ttm roe -9.6% vs 23.1%.

Is XERS's lead over XENE getting stronger or weaker?

XERS lead: Stable — the AIQ differential has held near 29 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the XENE vs XERS verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XENE closes the Momentum gap — currently 65 points behind, the largest single contributor to XERS's edge; XENE's Death Cross Active resolves — a bearish trend rule currently active against it; XERS's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about XENE and XERS?

XENE: 0 bullish / 3 bearish / 2 neutral. XERS: 6 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on XENE is Death Cross Active (bearish, long horizon). On XERS it is Golden Cross Active (bullish, long horizon).

Compare XENE and XERS with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.